Research suggests that rutaecarpine exhibits a protective role in DKD by specifically targeting the VEGFR2/NLRP3 signaling pathway, thereby preventing or mitigating the inflammatory and pyroptosis that contribute to podocyte damage [108]. This evidence concerns the gene NLRP3 and diabetic kidney disease.